Skip to main content
. 2020 Apr 3;9(4):873. doi: 10.3390/cells9040873

Figure 7.

Figure 7

IL7 and IL12 secreting MSCs support an anti-tumor response in vivo. NSG mice (5–12 animals/group) were subcutaneously co-injected with LS174T tumor cells (2.5 × 106/mouse), anti-CEA CAR T cells or non-modified T cells (2 × 106/mouse) in presence or absence of non-modified or IL7 and IL12 secreting MSCs (4 × 105/mouse). Tumor growth was monitored every 2–3 days. Onset of tumor growth was determined at tumor size >20 mm3. The experiment was terminated on day 58. (A) Tumor growth of individual animals; red line represents mean values. (b–d) Kaplan Meier plots of data with tumor free survival. (B) Comparison of groups with non-modified and CAR T cells; (C) comparison of groups with non-modified T cells in presence or absence of MSCs and IL7/IL12 secreting MSCs; (D) comparison of groups with CAR T cells in presence or absence of MSCs and IL7/IL12 secreting MSCs. Statistical analysis was determined by the Logrank-test.